Rofecoxib - Tremeau Pharmaceuticals

Alternative Names: TRM 201

Latest Information Update: 19 Dec 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Tremeau Pharmaceuticals
Class Antirheumatics; Lactones; Non-opioid analgesics; Sulfones
Mechanism of Action Cyclo-oxygenase 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Joint disorders
New Molecular Entity No

Highest Development Phases

Phase II Joint disorders

Most Recent Events

12 Dec 2017 Tremeau Pharmaceuticals and the US FDA Agree on phase III plan for Haemophilic arthropathy
05 Dec 2017 Chemical structure information added
22 Nov 2017 Rofecoxib- Tremeau Pharmaceuticals receives Orphan Drug status for Joint disorders (haemophilic arthropathy) in USA

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.